THREAD Enhances Digital Therapeutics (DTx) Studies with Clinical Research Technology
Purpose-built solution combines THREAD’s no-code clinical research platform, parallel DTx study workflows, and research expertise for customers
CARY, N.C., 03 NOV 2026 – THREAD, a leading no-code clinical research technology platform with scientific consulting for decentralized clinical trials (DCT) and electronic clinical outcome assessments (eCOA), today announced new technology features being utilized to enable complex Digital Therapeutics (DTx) studies on the platform. The companies’ purpose-built approach was designed with DTx customers to offer DTx specific configurations, integration functionality with the DTx to provide a single experience without intervention challenges and address a variety of design requirements not available in other platforms for a more fit-for-purpose solution.
Digital therapeutic studies have unique research requirements that require the patient/caregiver app and research site portal to work in parallel with the DTx. THREAD’s DTx solution is designed to bring these components together within a connected research environment, helping developers evaluate safety, efficacy, engagement, adherence, and patient outcomes, making it less complex to conduct a DTx study.
The solution provides DTx sponsors with access to a comprehensive set of configurable clinical research capabilities, including:
- Digital health technology integrations to incorporate data from DTx platforms and third-party connected devices, sensors, and wearables
- Ability to capture every DTx data point via eConsent, eCOA, eDiary, DHT and CRFs in the clinic and at home via telehealth virtual visits
- Participant engagement and retention tools that support both the study and DTx alerts without creating unwanted interventions
- Real-time reporting and analytics to provide study teams with greater visibility into study performance
“Digital therapeutic studies require a research approach that can move at the speed of the technology, integrative differently than drug studies and include the high-quality rigor required for clinical evidence generation,” said John Reites, Co-Founder, CEO of THREAD. “We are so grateful to work with our DTx sponsors and their CROs utilizing our approach as their partner.”
Learn more about THREAD’s Digital Therapeutics (DTx) solution, visit https://www.threadresearch.com/fit-for-purpose-solutions/digital-therapeutics-dtx.
##
About THREAD
THREAD’s® purpose is to leverage its clinical research platform to enable studies for everyone, everywhere. Through its uniquely combined research technology and scientific consulting services, THREAD helps life science organizations to design, operate, and scale next-generation research studies and electronic clinical outcome assessments (eCOA) programs for participants, sites, and study teams. Through its comprehensive platform and scientific expertise, THREAD empowers studies to be accessible, efficient, and human-centered.
THREAD has been recognized as a leader by Everest Group in its Decentralized Clinical Trial Product PEAK Matrix® Assessments from 2021 through 2023, is positioned in the Leaders Category of the 2022 IDC MarketScape for R&D Decentralized Clinical Trial Technology Solutions Vendor Assessment, and is named a Major Contender in Everest Group’s Life Sciences eCOA Products PEAK Matrix® Assessment 2025.
Media Contact
Les Yates
THREAD
media@THREADresearch.com
THREAD® provides a fully configurable clinical research platform to enable studies for everyone, everywhere. Through its industry-leading technology and scientific expertise, we empower studies to be more accessible, efficient, and patient-centered.